[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iiiii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iiiii":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100630570","concomitant-use-of-radiotherapy-and-integrated-exercise---lung-cancer-100630570",false,"NCT07489391","Concomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer","Effect of an Integrated Exercise Program Concomitant With Radiotherapy on Functional Capacity in Patients With Lung Cancer","Inclusion Criteria:\n\n* Histological diagnosis of non-small cell lung cancer (NSCLC) at stage II-III (locally advanced), unresectable\u002Finoperable.\n* Candidate for radical radiotherapy with concomitant chemotherapy, with or without maintenance Durvalumab.\n* ECOG performance status ≤2 (or Karnofsky index ≥60).\n* Ability to communicate adequately with the research team and to complete questionnaires and functional tests.\n* Signed written informed consent after receiving detailed information about the study.\n\nExclusion Criteria:\n\n* Decompensated cardiorespiratory comorbidities that contraindicate moderate-intensity physical exercise:\n\n  * New York Heart Association (NYHA) class III-IV congestive heart failure or unstable angina.\n  * Recent myocardial infarction (\\\u003C6 months) or uncontrolled arrhythmias.\n  * Very severe chronic obstructive pulmonary disease (COPD) GOLD IV with recent exacerbations, permanent home oxygen therapy, or severe pulmonary hypertension.\n* Severe physical or neurological limitations that prevent exercise.\n* Absolute medical contraindications to inspiratory muscle training: unresolved pneumothorax, recent thoracic surgery (\\\u003C4 weeks), or active hemoptysis.\n* Refusal or inability to understand\u002Ffollow the program instructions (e.g., severe cognitive impairment, insurmountable language barrier).","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","Study objective and procedures\n\nThe objective of CURIE-LC is to evaluate the feasibility (i.e., whether it is possible and safe) of carrying out a comprehensive exercise program during combined radiotherapy and chemotherapy in patients with lung cancer. The study will assess whether patients can adhere to the exercise program while receiving oncologic treatment and will explore its effects on physical fitness and quality of life.\n\nWhat does participation involve?\n\nIf participants choose to take part, they will join a supervised exercise program conducted throughout the chemoradiotherapy treatment. The program includes three main components, tailored to the individuals' abilities:\n\nInspiratory breathing exercise: training with a specialized device to strengthen the breathing muscles and improve lung capacity.\n\nAerobic exercise: moderate-intensity aerobic activity (e.g., treadmill walking or stationary cycling) several days per week to improve endurance and cardiovascular health.\n\nStrength training: muscle-strengthening exercises (e.g., light weights or resistance bands) twice per week to maintain or increase arm and leg strength.\n\nA physiotherapist or other trained professional will guide the participant at all times to ensure exercises are performed safely and appropriately. Sessions will last approximately 20 to 60 minutes and will be coordinated with the radiotherapy\u002Fchemotherapy schedule so as not to interfere with the treatment.\n\nIn addition to the exercise sessions, participants will undergo physical assessments and complete questionnaires at several time points. Before starting and at the end of the program, the investigagtors will measure functional capacity using the 6-minute walk test (6MWT) and assess respiratory muscle strength using maximal inspiratory and expiratory pressures (PImax and PEmax). Handgrip strength will also be measured. Participants will complete questionnaires about health status, fatigue, mood, and quality of life. These evaluations will help determine the impact of exercise during treatment.\n\nThe exercise program will last for the duration of the treatment, approximately 7 to 9 weeks, with a short-term follow-up after treatment ends. Overall, participation involves attending the scheduled weekly exercise sessions during treatment, plus several evaluation visits (before, during, at the end of the program, and a few months later). Exact timing and frequency will be explained and planned according to the individual situation, aiming to minimize disruption to daily routine.",[26,27,28],"Non Small Cell Lung Cancer","Radiation Therapy Patient","Stage II\u002FIII",[30,31,32],"Lung Cancer","Exercise","Radiochemotherapy","RECRUITING","2026-04-30",{"date":36,"type":37},"2026-05-06","ACTUAL",{"date":39,"type":20},"2026-04",{"date":41,"type":20},"2026-12",{"name":43,"class":44},"University of Deusto","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100598292","phase-2-predict-rd-ctdna-surveillance-in-tnbc-with-residual-disease-100598292","NCT07069595","PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC With Residual Disease","PREDICT-RD","Inclusion Criteria:\n\nWritten informed consent was obtained to participate in the study, and HIPAA authorization for the release of personal health information.\n\n* Participant is willing and able to comply with study procedures based on the judgment of the investigator.\n* Age ≥ 18 years at the time of consent.\n* Histological confirmation of TNBC defined by ER\u002FPR \\\u003C10%, HER2 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative.\n* Stage II\u002FIII TNBC treated with neoadjuvant systemic therapy AND have residual disease defined as RCB II\u002FIII at time of surgery.\n* Baseline staging scans at the discretion of the treating physician and demonstrate no evidence of metastatic disease.\n* The participant must have archival diagnostic tissue and\u002For surgical resection tissue Available.\n* Participants are willing and able to comply with study procedures based on the judgment of the investigator.\n\nExclusion Criteria:\n\n• Participants are pregnant or breastfeeding.",{"count":54,"type":20},78,[56],"PHASE2","This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II\u002FIII triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II\u002FIII after conventional neoadjuvant chemo-immunotherapy followed by surgery. Technological advances in ctDNA assays have improved both the sensitivity and reliability of molecular residual disease (MRD) detection to enable real-time measurement with clinical-grade assays.\n\nThe primary objective of this study will be to evaluate ctDNA-based MRD status in high-risk, early-stage TNBC patients by defining the proportion of TNBC patients with MRD-only recurrence (ctDNA positive without radiographically measurable recurrence) during post-surgery surveillance. The secondary objectives will evaluate the safety, preliminary efficacy, and survival outcomes of using Dato-DXd in participants with MRD-only TNBC.\n\nDato-DXd is an investigational antibody-drug conjugate (monoclonal antibody specific for TROP2 and a topoisomerase I (Topo-1) inhibitor) that has demonstrated promising efficacy in TNBC patients with a manageable safety profile.",[59,60,61,28],"Breast Cancer","Residual Disease","Triple Negative Breast Cancer (TNBC)",[63,64,65],"circulating tumor DNA (ctDNA)","surveillance","Dato-DXd","2026-04-21",{"date":68,"type":37},"2026-04-22",{"date":70,"type":37},"2026-02-26",{"date":72,"type":20},"2032-11-01",{"name":74,"class":44},"UNC Lineberger Comprehensive Cancer Center",1]